Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cytochrome P450 2D6 (CYP2D6) is a hepatic enzyme responsible for metabolizing approximately 25% of all prescription medications, including antidepressants, beta-blockers, and opioids. This enzyme converts prodrugs into active metabolites and facilitates the elimination of xenobiotics through phase I oxidative metabolism.
Reported Benefits (Provisional)
Origin & History
Cytochrome P450 2D6 (CYP2D6) is an enzyme found in the liver, playing a key role in the metabolism of drugs and toxins. It is part of the cytochrome P450 family, which is involved in the oxidative metabolism of various substances.
Research Narrative (Provisional)
Research includes pharmacogenetic studies and clinical trials examining CYP2D6's role in drug metabolism and personalized medicine.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Part of the cytochrome P450 enzyme family. - Genetic polymorphisms significantly affect enzyme activity. - Involved in the metabolism of approximately 25% of drugs.
Reported Mechanism (Provisional)
CYP2D6 catalyzes oxidative metabolism through heme-mediated electron transfer, primarily hydroxylating substrates like codeine to morphine and metabolizing SSRIs such as fluoxetine and paroxetine. The enzyme operates via cytochrome P450 reductase-mediated electron transfer from NADPH, enabling substrate oxidation at the heme iron center. CYP2D6 also metabolizes endogenous compounds including tyramine, serotonin, and dopamine, influencing neurotransmitter homeostasis.
Clinical Narrative (Provisional)
Pharmacogenetic studies involving over 10,000 patients demonstrate that CYP2D6 polymorphisms significantly affect drug metabolism, with poor metabolizers (7-10% of Caucasians) showing 5-10 fold higher drug concentrations. Clinical trials indicate that CYP2D6 genotyping reduces adverse drug reactions by 30-50% for medications like tramadol and tamoxifen. Meta-analyses of 50+ studies confirm that CYP2D6 variants directly correlate with therapeutic outcomes for antidepressants, with ultra-rapid metabolizers requiring 2-3 fold higher doses. However, most evidence comes from observational studies rather than randomized controlled trials specifically targeting CYP2D6 function enhancement.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.